Pathology of malignant melanoma

Surgical Clinics of North America

Volumn 83, Issue 1, 2003, Pages 31-60

  Liu, Vincent ^a   Mihm, Martin C ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CANCER INVASION; CANCER SIZE; CANCER STAGING; CARCINOMA IN SITU; DIFFERENTIAL DIAGNOSIS; DNA MICROARRAY; DYSPLASTIC NEVUS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; JUVENILE MELANOMA; MALIGNANT LENTIGO; MELANOMA; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; SKIN CARCINOGENESIS; THICKNESS;

EID: 0037302994     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(03)00003-3     Document Type: Review

References (94)

1. Crowson AN, Magro CM, Mihm MC. The melanocytic proliferations: a comprehensive textbook of pigmented lesions. New York: Wiley-Liss; 2001.
2. Sagebiel RW. The dysplastic melanocytic nevus. J Am Acad Dermatol 1989;20:496-501.
3. Clark WH Jr, Ackerman AB. An exchange of views regarding the dysplastic nevus controversy. Semin Dermatol 1989;8:229-50.
4. Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi. Markers for increased risk for melanoma. Cancer 1989;63:386-9.
5. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. JAMA 1997;277(18):1439-44.
6. Albert LS, Rhodes AR, Sober AJ. Dysplastic nevi and cutaneous melanoma: markers of increased melanoma risk for affected persons and blood relatives. J Am Acad Dermatol 1990;22:69-75.
7. Clemente C, Cochran AJ, Elder DE, et al. Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol 1991;22:313-9.
8. Barnhill RI, Roush GC. Correlation of clinical and histopathologic features in clinically atypical melanocytic nevi. Cancer 1991;67:3157-64.
9. Spitz S. Melanomas of childhood. Am J Path 1948;24:591-609.
10. Weedon D, Little JH. Spindle and epithelioid cell nevi in children and adults. A review of 211 cases of the Spitz nevus. Cancer 1977;40:217-25.
11. Kaye VN, Delner LP. Spindle and epithelioid cell nevus (Spitz nevus). Natural history following biopsy. Arch Dermatol 1990;126:1581-3.
12. Kamino H, Flotte TJ, Msuloff E. Eosinophilic globules in Spitz's nevi. New findings and a diagnostic sign. Am J Dermatopathol 1979;1:319-24.
13. Busam KJ, Barnhill RL. Pagetoid Spitz nevus. Intraepidermal Spitz tumor with prominent pagetoid spread. Am J Surg Pathol 1995;19(9):1061-7.
14. Barnhill RL, Argenyi ZB, From L, et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol 1999;30(5):513-20.
15. Smith KJ, Barrett TL, Skelton HG III, et al. Spindle cell and epithelioid cell nevi with atypia and metastasis (malignant Spitz nevus). Am J Surg Pathol 1989;13:931-9.
16. Reed RJ, Ichinose H, Clark WH, et al. Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol 1975;2:119-47.
17. Sagebiel RW, Chinn EK, Egbert BM. Pigmented spindle cell nevus. Clinical and histologic review of 90 cases. Am J Surg Pathol 1984;8(9):645-53.
18. Rock B, Hood AF, Rock JA. Prospective study of vulvar nevi. J Am Acad Dermatol 1990;22:104-6.
19. Clark WH Jr, Hood AF, Tucker MA, et al. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia. Hum Pathol 1998;29:1-24.
20. Clark WH Jr, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969;29:705.
21. Tannous ZS, Lerner LH, Duncan LM, et al. Progression to invasive melanoma from malignant melanoma in situ, lentigo maligna type. Hum Pathol 2000;31(6):705-8.
22. Elder DE, Guerry D IV, Epstein MN, et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol 1984;6:55.
23. McGovern VJ, Mihm MC, Bailly C, et al. The classification of malignant melanoma and its histologic reporting. Cancer 1973;32:1446-57.
24. Price NM, Rywlin AM, Ackerman AB. Histologic criteria for the diagnosis of superficial spreading malignant melanoma. Cancer 1976;38:2434.
25. Clark WH, Mihm MC. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol 1969;55:39.
26. Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987;116:303.
27. Coleman WP 3rd, Loria PR, Reed RJ, Krementz ET. Acral lentiginous melanoma. Arch Dermatol 1980;116:773-6.
28. Clark WH Jr, Elder DE, Van Horn M. The biologic forms of malignant melanoma. Hum Pathol 1986;5:443.
29. Plotnick H, Rachiamolf M, Van du Berg HJ Jr Polypoid melanoma: a virulent variant of nodular melanoma. J Am Acad Dermatol 1990;23:880-4.
30. Phillips ME, Margolis RJ, Merot Y, et al. The spectrum of minimal deviation melanoma: a clinicopathologic study of 21 cases. Hum Pathol 1986;17:796.
31. Schmoeckel C, Castro CE, Braun-Falco O. Nevoid malignant melanoma. Arch Dermatol Res 1985;277:362.
32. Wong TY, Suster S, Duncan LM, et al. Nevoid melanoma: a clinicopathological study of seven cases of malignant melanoma mimicking spindle and epithelioid cell nevus and verrucous dermal nevus. Hum Pathol 1995;26:171-9.
33. Blessing K, Grant JJ, Sanders DS, et al. Small cell malignant melanoma: a variant of naevoid melanoma. Clinicopathological features and histological differential diagnosis. J Clin Pathol 2000;53(8):591.
34. McNutt NS, Urmacher C, Hakimian J, et al. Nevoid malignant melanoma: morphologic patterns and immunohistochemical reactivity. J Cutan Pathol 1995;22:502.
35. Scalzo DA, Hida CA, Toth G, et al. Childhood melanoma: a clinicopathological study of 22 cases. Melanoma Res 1997;7(1):63-8.
36. Barnhill RLW, Flotte TJ, Fleischli M, et al. Cutaneous melanoma and atypical Spitz tumors in childhood. Cancer 1995;76:1833.
37. Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma. Cancer 1971;28:914.
38. Carlson JA, Dickersin GR, Sober AJ, et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 28 cases. Cancer 1995;75:478-94.
39. Levene A. Equine melanotic disease. Tumori 1971;57(3):133-68.
40. Crowson AN. Magro CM, Mihm MC Jr Malignant melanoma with prominent pigment synthesis with "animal type" melanoma. Hum Pathol 1999;30(5):543-50.
41. Mihm MC, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996;74:43.
42. Abernethy JL, Soyer HP, Kerl H, et al. Epidermotropic metastatic malignant melanoma simulating melanoma in situ: a report of 10 examples from two patients. Am J Dermatopathol 1994;18:1140.
43. Clark WH, Elder DE, Guerry D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893.
44. Day CL, Mihm MC, Sober AJ, et al. Prognostic factors for melanoma patients with lesions 0.76-1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg 1982;195:30-4.
45. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995;75:2484-91.
46. Schuchter L, Schultz DJ, Synnestvedt M, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. Ann Intern Med 1996;125:369-75.
47. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902.
48. Blois MS, Sagebiel RW, Abarbanel RM, et al. Malignant melanoma of the skin. I. The association of tumor depth and type, and patient sex, age, and site with survival. Cancer 1983;52:1330-41.
49. Prade M, Bognel C, Charpentier P, et al. Malignant melanoma of the skin: prognostic factors derived from a multifactorial analysis of 239 cases. Am J Dermatopathol 1982;4:411-2.
50. Kelly JW, Sagebiel RW, Clyman S, et al. Thin level IV malignant melanoma: a subset in which level is the major prognostic indicator. Ann Surg 1985;202:98.
51. Buttner P, Garbe C, Bertz J, et al. Primary cutaneous melanoma: optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995;75:2499.
52. Cochran AJ. Histology and prognosis in malignant melanoma. J Pathol 1969;97:459.
53. Kopf AW, Gross DF, Rogers GS, et al. Prognostic index for malignant melanoma. Cancer 1987;59:1236-41.
54. Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980;45:3012.
55. Day CL, Lew RA, Harrist TJ. Malignant melanoma prognostic factors: ulceration width. J Dermatol Surg Oncol 1984;10:23-4.
56. Clemente CG, Mihm MC, Bufalino R, et al. Prognostic value of tumor-infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-10.
57. Ronan SG, Eng AM, Briele HA, et al. Thin malignant melanomas with regression and metastases. Arch Dermatol 1987;123:1326-30.
58. Day CL, Harrist TJ, Gorstein F, et al. Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg 1981;194:108-12.
59. Leon P, Daly JM, Synnestvedt M, et al. The prognostic implication of microscopic satellites in patients with clinical stage I melanoma. Arch Surg 1991;126:1461-8.
60. Statius Muller MG, van Leeuwen PAM, de Lange-de Klerk ESM, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer 2001;91:2401-8.
61. Duncan LM. Prognostic indicators in melanoma. Chapter 17 in Advances in Dermatology, Volume 15. St. Louis: Mosby, 1999.
62. Heenan PJ, Jarvis LR, Armstrong BK. Nuclear indices and survival in cutaneous melanoma. Am J Dermatopathol 1989;11:308-12.
63. Sorensen FB, Kristensen IB, Grymer F, et al. DNA level, tumor thickness, and sterological estimates of nuclear volume in stage 1 cutaneous malignant melanomas. Am J Dermatopathol 1991;13:11-9.
64. Gambini C, Casazza S, Borgiani L, et al. Counting the nucleolar organizer region-associated proteins is a prognostic clue of malignant melanoma. Arch Dermatol 1992;128:487-90.
65. Ramsay JA, From L, Iscoe NA, et al. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 1995;105:22-6.
66. Hazan C, Melzer K, Panageas KS, et al. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer 2002;95(3):634-40.
67. Vecchiato A, Rossi CR, Montesco MC, et al. Proliferating cell nuclear antigen (PCNA) and recurrence in patients with cutaneous melanoma. Melanoma Res 1994;4:207-11.
68. Essner R, Kuo CT, Wang H, et al. Prognostic implication of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. Cancer 1998;82:309-16.
69. Clurman BE, Groudine M. The CDKN2A tumor-suppressor locus- a tale of two proteins. N Engl J Med 1998;338:910-2.
70. Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998;338:879-87.
71. Duncan L, Deeds J, Hunter J, et al. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 1998;58:1515-20.
72. Johnson JP, Stade BG, Holzmann B, et al. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA 1989;86:641-54.
73. Schadendorf D, Gawlik C, Haney U, et al. Tumor progression and metastatic behavior in vivo correlates with integrin expression on melanocytic tumors. J Pathol 1993;170:429.
74. Natali PG, Hamby CV, Felding-Habermann B, et al. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion omolecule-expression in cutaneous malignant melanoma lesions. Cancer Res 1997;57:1554-60.
75. Kageshita T, Hamby CV, Ishihara T, Matsumoto K, Saida T, Ono T. Loss of [beta]-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol 2001;145(2):210-6.
76. Elder DE, Rodeck U, Thurin J, et al. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res 1989;49:5091-6.
77. Huang S, DeGuzman A, Bucana CD, et al. Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 2000;6(6):2573-81.
78. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002;99(22):14374-9.
79. Chen YT, Stockert E, Chen Y, et al. Identification of the MAGE-gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci USA 1994;91(3):1004-8.
80. Hofbauer GF, Schaefer C, Noppen C, et al. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997;151(6):1549-53.
81. Donato R. Functional role of S 100 proteins, calcium-binding proteins of the EF-hand type. Biochem Biophys Acta 1999;1450(3):191-231.
82. Acland K, Evans AV, Abraha H, et al. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol 2002;146(5):832-5.
83. Hochberg M, et al. Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma. Br J Dermatol 2002;146(2):244-9.
84. Bahwan J. Mel-5: a novel antibody for differential diagnosis of epidermal pigmented lesions of the skin in paraffin-embedded sections. Melanoma Res 1997;7(1):43-8.
85. King R, Googe PB, Weilbaecher KN, et al. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and non-melanocytic tumors. Am J Surg Pathol 2001;25(1):512-57.
86. Salti GI, Manougian T, Farolan M, et al. Microphthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 2000;60(18):5012-6.
87. Bostick PJ, Morton DL, Turner RR, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999;17(10):3238-44.
88. Blaheta HJ, Schittek B, Breuninger H, et al. Detection of micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastastic disease in the lymph node basin. Am J Surg Pathol 1999;23(7):822-8.
89. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg 1999;230(4):453-63.
90. Bittner M. Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406(6795):536-40.
91. Su YA, Bittner ML, Chen Y, et al. Identification of tumor-suppressor genes using human melanoma cell lines UACC903, UACC903(+6), and SRS3 by comparison of expression profiles. Mol Carcinogen 2000;28(2):119-27.
92. Yu LL, Flotte TJ, Tanabe KK, et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 1999;86(4):617-27.
93. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer Staging System for cutaneous melanoma. J Clin Onc 2001;19(16):3635-48.
94. Harrist TJ, Rigel DS, Day CL Jr, et al. Microscopic satellites are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 1984;53(10):2183-7.